Vitiligo secondary to immunosuppressants: a pharmacovigilance study of the FDA Adverse Event Reporting System - PubMed
6 hours ago
- #vitiligo
- #pharmacovigilance
- #immunosuppressants
- Study analyzes FAERS data from 2004-2024 to link immunosuppressants with vitiligo.
- 435 vitiligo adverse event reports identified, mostly from the US, Canada, and European countries.
- Reports were more common in females aged 18-65, with psoriasis and arthritis as main indications.
- Adalimumab and secukinumab had the highest number of reports.
- Significant signals detected for alemtuzumab, ixekizumab, ustekinumab, secukinumab, guselkumab, and risankizumab.
- Highlights need for ongoing pharmacovigilance and further research into mechanisms.